Ann Surg Treat Res.
2018 Mar;94(3):166-166. 10.4174/astr.2018.94.3.166.
CORRIGENDUM: Correction of funding statement in ACKNOWLEDGEMENTS section: Epigenetic inactivation of RUNX3 in colorectal cancer
- Affiliations
-
- 1Department of Surgery, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 2Department of Hematology and Oncology, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 3Department of Obstetrics and Gynecology, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 4Medical Science Research Institute, Soonchunhyang University, Cheonan, Korea.
- 5Department of Anatomy, Kyungpook National University School of Medicine, Daegu, Korea.
- 6Soonchunhyang University College of Medicine, Cheonan, Korea.
- KMID: 2405331
- DOI: http://doi.org/10.4174/astr.2018.94.3.166
Abstract
- Correction of funding statement in ACKNOWLEDGEMENTS section.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- ERRATUM: Correction of funding statement in ACKNOWLEDGEMENTS section. Effectiveness of thymoquinone, zeolite, and platelet-rich plasma in model of corrosive oesophagitis induced in rats
- A Validation Study of Child Health-6 Dimension (CH-6D), a Generic Preference-Based Health-Related Quality of Life Measure
- RUNX3 Methylation Status in Colonic Carcinoma and Adenoma
- Epigenetic inactivation of RUNX3 in colorectal cancer
- Addition of funding statement: Clinical characteristics of papillary thyroid carcinoma arising from the pyramidal lobe
